Physicians' Academy for Cardiovascular Education

Low baseline SBP associated with higher mortality in HF patients

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF

Literature - Böhm M, Young R, Jhund PS, et al. - Eur Heart J. 2017; published online ahead of print

Main results

Conclusion

Although at higher risk for all-cause mortality, CV mortality and heart failure hospitalisation, heart failure patients with reduced ejection fraction of the PARADIGM-HF study with low SBP at baseline and on sacubitril/valsartan had the same relative benefit over enalapril as patients with higher baseline SBP. However, hypotension-related adverse effects were more often observed in the sacubitril/valsartan arm.

References

Show references

Find this article online at Eur Heart J

Share this page with your colleagues and friends: